home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9603.zip
/
M9630468.TXT
< prev
next >
Wrap
Text File
|
1996-02-27
|
2KB
|
33 lines
Document 0468
DOCN M9630468
TI Virus validation experiments on the production process of OCTAVI SDPlus.
DT 9603
AU Biesert L; Lemon S; Suhartono H; Wang L; Rubsamen H;
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus,; Frankfurt am
Main, Germany.
SO Blood Coagul Fibrinolysis. 1995 Jul;6 Suppl 2:S48-54. Unique Identifier
: AIDSLINE MED/96076199
AB The inactivation of both transfusion-relevant and model viruses by
modified pasteurization has been evaluated following the established
guidelines of the European Union Committee for Proprietary Medical
Products Ad Hoc Working Party on Biotechnology/Pharmacy. This heat
treatment in solution for 10 h at 63 degrees C was introduced into the
manufacturing process of OCTAVI, a very high purity factor VIII
concentrate stabilized by von Willebrand factor. It could be
demonstrated that both enveloped (human immunodeficiency virus, herpes
simplex virus, pseudorabies virus) and non-enveloped viruses
(poliovirus, coxsackievirus, hepatitis A virus) were inactivated by this
heating step with an efficacy of greater than 4.5 log10 TCID50. The
combination of the solvent/detergent step already used in the
manufacture with this modified pasteurization leads to a double
virus-inactivated factor VIII concentrate (OCTAVI SDPlus) with a viral
safety distinctly superior to monoinactivated products.
DE *Antiviral Agents Blood Banks/*STANDARDS *Blood Donors Blood
Transfusion/*ADVERSE EFFECTS Detergents European Economic Community
Factor VIII/*ISOLATION & PURIF Guidelines Heat Human Reproducibility
of Results Solvents JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).